Ind-Swift Laboratories Limited INDSWFTLAB.NS Stock
Ind-Swift Laboratories Limited Price Chart
Ind-Swift Laboratories Limited INDSWFTLAB.NS Financial and Trading Overview
| Ind-Swift Laboratories Limited stock price | 105.5 INR |
| Previous Close | 73.05 INR |
| Open | 74 INR |
| Bid | 73.8 INR x 0 |
| Ask | 73.9 INR x 0 |
| Day's Range | 72.2 - 75.8 INR |
| 52 Week Range | 52.65 - 80 INR |
| Volume | 196.28K INR |
| Avg. Volume | 93.34K INR |
| Market Cap | 4.36B INR |
| Beta (5Y Monthly) | -0.031849 |
| PE Ratio (TTM) | 8.763377 |
| EPS (TTM) | 71.24 INR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | September 20, 2011 |
| 1y Target Est | N/A |
INDSWFTLAB.NS Valuation Measures
| Enterprise Value | 12.68B INR |
| Trailing P/E | 8.763377 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.36079487 |
| Price/Book (mrq) | 0.63798475 |
| Enterprise Value/Revenue | 1.051 |
| Enterprise Value/EBITDA | 5.534 |
Trading Information
Ind-Swift Laboratories Limited Stock Price History
| Beta (5Y Monthly) | -0.031849 |
| 52-Week Change | 21.44% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 80 INR |
| 52 Week Low | 52.65 INR |
| 50-Day Moving Average | 67.88 INR |
| 200-Day Moving Average | 63.27 INR |
INDSWFTLAB.NS Share Statistics
| Avg. Volume (3 month) | 93.34K INR |
| Avg. Daily Volume (10-Days) | 80.75K INR |
| Shares Outstanding | 59.09M |
| Float | 30.45M |
| Short Ratio | N/A |
| % Held by Insiders | 67.78% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 3.94% |
| Operating Margin (ttm) | 14.23% |
| Gross Margin | 45.69% |
| EBITDA Margin | 18.98% |
Management Effectiveness
| Return on Assets (ttm) | 5.92% |
| Return on Equity (ttm) | 7.42% |
Income Statement
| Revenue (ttm) | 12.07B INR |
| Revenue Per Share (ttm) | 204.45 INR |
| Quarterly Revenue Growth (yoy) | 1.89% |
| Gross Profit (ttm) | 5.85B INR |
| EBITDA | 2.29B INR |
| Net Income Avi to Common (ttm) | 475.97M INR |
| Diluted EPS (ttm) | 8.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 182M INR |
| Total Cash Per Share (mrq) | 3.08 INR |
| Total Debt (mrq) | 8.62B INR |
| Total Debt/Equity (mrq) | 126.42 INR |
| Current Ratio (mrq) | 3.138 |
| Book Value Per Share (mrq) | 115.52 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.95B INR |
| Levered Free Cash Flow (ttm) | 353.17M INR |
Profile of Ind-Swift Laboratories Limited
| Country | India |
| State | N/A |
| City | Manimajra |
| Address | Shivalik Enclave |
| ZIP | 160101 |
| Phone | 91 17 2506 1850 |
| Website | https://www.indswiftlabs.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India.
Q&A For Ind-Swift Laboratories Limited Stock
What is a current INDSWFTLAB.NS stock price?
Ind-Swift Laboratories Limited INDSWFTLAB.NS stock price today per share is 105.5 INR.
How to purchase Ind-Swift Laboratories Limited stock?
You can buy INDSWFTLAB.NS shares on the NSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ind-Swift Laboratories Limited?
The stock symbol or ticker of Ind-Swift Laboratories Limited is INDSWFTLAB.NS.
Which industry does the Ind-Swift Laboratories Limited company belong to?
The Ind-Swift Laboratories Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Ind-Swift Laboratories Limited have in circulation?
The max supply of Ind-Swift Laboratories Limited shares is 59.09M.
What is Ind-Swift Laboratories Limited Price to Earnings Ratio (PE Ratio)?
Ind-Swift Laboratories Limited PE Ratio is 1.48090970 now.
What was Ind-Swift Laboratories Limited earnings per share over the trailing 12 months (TTM)?
Ind-Swift Laboratories Limited EPS is 71.24 INR over the trailing 12 months.
Which sector does the Ind-Swift Laboratories Limited company belong to?
The Ind-Swift Laboratories Limited sector is Healthcare.